BRCAPRO model underestimates BRCA1/2 mutation risk

BRCAPRO model underestimates <i>BRCA1/2</i> mutation risk

(HealthDay)—Use of the BRCAPRO model for assessment of the likelihood of having a germline BRCA1/BRCA2 mutation, based on age, ethnicity, and family history, may underestimate the risk of mutations, according to a study published online March 17 in the Journal of Clinical Oncology.

Molly S. Daniels, from the University of Texas MD Anderson Cancer Center in Houston, and colleagues calculated BRCAPRO scores for 589 patients with referred for at three institutions. The BRCAPRO predictions were compared with observed mutations.

The researchers found that 31 percent of patients with ovarian cancer tested positive for BRCA1 or BRCA2 mutation. More mutations were observed than expected with BRCAPRO scores <40 percent (93 mutations observed versus 34.1 mutations expected; P < 0.001). Twenty-eight percent of mutations (51 of 180) would have been missed if patients with BRCAPRO scores <10 percent had not been tested. The risk for high-grade serous ovarian cancers was underestimated with BRCAPRO, but it overestimated the risk for other histologies (P < 0.001). Underestimation increased with decreasing age at diagnosis, and there was institution-level variation in model performance (both P = 0.02).

"This study demonstrates that assessment of by a validated model cannot effectively target testing to a high-risk ovarian cancer patient population, which strongly supports the recommendation to offer BRCA1/BRCA2 genetic testing to all patients with high-grade serous ovarian cancer regardless of family history," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Gene test aids cancer profile

8 hours ago

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

How a common antacid could lead to cheaper anti-cancer drugs

Nov 26, 2014

A popular indigestion medication can increase survival in colorectal cancer, according to research published in ecancermedicalscience. But in fact, scientists have studied this for years - and a group of cancer advocates want t ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.